Evidence map›Paper›PMID 42442965›Full record

ArticleBreast (Edinburgh, Scotland)2026

Withdrawal notice to: "From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer" [The Breast 88 (2026) 104791].

Paulina Stachyra, Cristina Hernando Meliá, José Antonio López-Guerrero, Joaquín Gavilá Gregori, Ángel Luis Guerrero-Zotano

Abstract readRetraction Notice
In one paragraph

Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Paulina StachyraII Department of Oncology and Clinical Immunology with Day Chemotherapy, Oncology Centre of the Lublin Region, Lublin, Poland.
Cristina Hernando MeliáMedical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
José Antonio López-GuerreroLaboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Department of Pathology, Catholic University of Valencia 'San Vicente Mártir', Valencia, Spain; Joint Cancer Research Unit IVO-CIPF, Valencia, Spain.
Joaquín Gavilá GregoriMedical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Ángel Luis Guerrero-ZotanoMedical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Spanish Research Group in Breast Cancer (GEICAM), Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42442965
PMCPMC13424937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.